Dual specific CD19/CD22‑targeted chimeric antigen receptor T‑cell therapy for refractory diffuse large B‑cell lymphoma: A case report
Affiliations: Department of Hematology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P.R. China, Hebei Senlang Biotechnology Co., Ltd., Shijiazhuang, Hebei 050011, P.R. China
- Published online on: July 16, 2020 https://doi.org/10.3892/ol.2020.11882
- Article Number: 21
Copyright: © Huang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.